Derisking Psychiatric Drug Development: The NIMH's Fast Fail Program, A Novel Precompetitive Model.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

19 citing papers in PubMed.

1. Mismatch negativity as an index of target engagement for excitation/inhibition-based treatment development: a double-blind, placebo-controlled, randomized, single-dose cross-over study of the serotonin type-3 receptor antagonist CVN058.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2022
   Trial
2. Double blind, two dose, randomized, placebo-controlled, cross-over clinical trial of the positive allosteric modulator at the alpha7 nicotinic cholinergic receptor AVL-3288 in schizophrenia patients.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2020
   Trial
3. Application of the research domain criteria in early-phase clinical development of transdiagnostic neurotherapeutics: A multidisciplinary perspective.Neuroscience applied · 2026
   Review
4. Novel therapeutics in autism spectrum disorder.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026
   Review
5. Beyond Alzheimer's disease-translating biomarker insights across CNS diseases.Science translational medicine · 2025
   Review
6. A Blueprint for Translational Precision Medicine in Autism Spectrum Disorder and Related Neurogenetic Syndromes.Journal of child and adolescent psychopharmacology · 2025
   Review
7. Experimental Therapeutics: Opportunities and Challenges Stemming From the National Institute of Mental Health Workshop on Novel Target Discovery and Psychosocial Intervention Development.Perspectives on psychological science : a journal of the Association for Psychological Science · 2025
   Article
8. Biomarker Methodologies: A NIMH Perspective.Advances in neurobiology · 2024
   Review
9. Real changes can enhance information yield on novel psychopharmacologic agents.World psychiatry : official journal of the World Psychiatric Association (WPA) · 2023
   Article
10. Experimental Medicine Approaches in Early-Phase CNS Drug Development.Advances in neurobiology · 2023
    Article
11. Promises and challenges of human computational ethology.Neuron · 2021
    Review
12. Drug development for Autism Spectrum Disorder (ASD): Progress, challenges, and future directions.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology · 2021
    Review
13. Time to re-engage psychiatric drug discovery by strengthening confidence in preclinical psychopharmacology.Psychopharmacology · 2021
    Review
14. D-Serine: A Cross Species Review of Safety.Frontiers in psychiatry · 2021
    Review
15. Relationship of Brain Glutamate Response to D-Cycloserine and Lurasidone to Antidepressant Response in Bipolar Depression: A Pilot Study.Frontiers in psychiatry · 2021
    Article
16. Greater Dynamic and Lower Static Functional Brain Connectivity Prospectively Predict Placebo Response in Pediatric Generalized Anxiety Disorder.Journal of child and adolescent psychopharmacology · 2020
    Article
17. The NIMH 'Fast-Fail Trials' (FAST) Initiative: Rationale, Promise, and Progress.Pharmaceutical medicine · 2020
    Review
18. Redirecting the revolution: new developments in drug development for psychiatry.Expert opinion on drug discovery · 2019
    Article
19. A Proof-of-Mechanism Study to Test Effects of the NMDA Receptor Antagonist Lanicemine on Behavioral Sensitization in Individuals With Symptoms of PTSD.Frontiers in psychiatry · 2019
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

4 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as